ICMJE DISCLOSURE FORM

Dat	e : 10. november 2024			
You	ır Name:	Thomas Benfield		
Mai	nuscript Title:	Click or tap here to enter t	ext.	
	nuscript Number (if wn):			
are r third comi list a	elated to the content of yo parties whose interests ma mitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo		
	ollowing questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>	
perta antih In ite	ains to the epidemiology of hypertensive medication, ev	hypertension, you should yen if that medication is n port for the work reporte	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months.	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
Tim	e frame: Since the initial plan	-		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None		
	No time limit for this			
	item.			
			Click TAB in last row to add extra rows	
Tim	e frame: past 36 months			
2	2 Grants or contracts from			
	Grants or contracts from	i □ ivone		
	Grants or contracts from any entity (if not indicated in item #1 above).	Novo Nordisk Foundation	Unrestricted grant to my institution	
	any entity (if not indicated	Novo Nordisk	Unrestricted grant to my institution Unrestricted grant to my institution Unrestricted grant to my institution, principal	

	1	1	
		Pfizer	Unrestricted grant to my institution, principal
			investigator//clinical trial, advisory board
		Gilead Sciences	Unrestricted grant to my institution, principal investigator//clinical trial, advisory board
		MSD	Unrestricted grant to my institution, principal
			investigator, advisory board
		Segirus UK Limited	principal investigator // clinical trial
		Janssen	Advisory board, principal investigator // clinical trial
		Astra Zeneca	Advisory board, principal investigator // clinical trial
		Moderna Tx	Advisory board, principal investigator // clinical trial
		Sanofi	principal investigator // clinical trial
		STRIVE / INSIGHT / NIH	principal investigator // clinical trial
			principal investigation // comment in the
3	Royalties or licenses	⊠ None	
4	Consulting fees	□ None	
		GSK	
		Pfizer	
		MSD	
		Gilead	
		Janssen	
_			
5	Payment or honoraria for lectures, presentations,	□ None	I.
	speakers bureaus,	GSK	lecture
	manuscript writing or	Pfizer	lecture
	educational events	Gilead Sciences	lecture
	eddeational events	Astra Zeneca	lecture
		Bavarian Nordic	lecture
6	Payment for expert	⊠ None	
	testimony		
7	Support for attending	□ None	
,	meetings and/or travel	MSD	
	and the same of th	IVISD	
8	Patents planned, issued or	☒ None	
	pending		
9	Participation on a Data	□ None	
	Safety Monitoring Board	COPERNICUS	EU CT: 2022-501035-16-01
	or Advisory Board	ORAL	NCT04140903, EU CT 2019-002845-39
	·		1.0.0.11.0000, 20.01.2010.002040.00
10	Leadership or fiduciary	⊠ None	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	□ None	
	1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1		

		Novo Nordisk			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	⊠ None			
	services				
13	Other financial or non- financial interests	⊠ None			

Please place an "X" next to the following statement to indicate your agreement:

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Please save/export the filled in **form as PDF** before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date	e: Klik el	ller tryk for at	angive en dato.	
You	r name:	Bo Hasseriis Ha	nsen	
Mar	nuscript tit	le: Mod st	ørre gennemsigtighed: Uges	krift for Læger styrker fokus på interessekonflikter
Mar	nuscript nu	mber (if known): V205200	
are re third comn list a	elated to th parties wh nitment to relationshi	te content of your content of	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. ps/activities/interests as they relate to the current
perta antih In ite	nins to the expertensive m #1 below	epidemiology of e medication, ev v, report all sup	hypertension, you should ven if that medication is n	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months. Specifications/Comments
			whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
Time	e frame: Sin	ce the initial plan	nning of the work	
1	manuscript provision o materials, i	medical writing, cessing charges,	⊠ None	
				Click TAB in last row to add extra rows
Time	e frame: pas	t 36 months		
2		ontracts from (if not indicated above).	⊠ None	
3	Royalties o	r licenses	⊠ None	

4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	⊠ None	
	educational events		
6	Payment for expert	⊠ None	
	testimony		
7	Support for attending	⊠ None	
	meetings and/or travel		
8	Patents planned, issued or	M Name	
0	pending	⊠ None	
	pending		
9	Participation on a Data	⊠ None	
	Safety Monitoring Board		
	or Advisory Board		
10	Leadership or fiduciary	⊠ None	
	role in other board,		
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	⊠ None	
12	Possint of aguinment	M Name	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
13	Other financial or non- financial interests	⊠ None	

Please place an "X" next to the following statement to indicate your agreement:

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

ICMJE DISCLOSURE FORM

Please save/export the filled in **form as PDF** before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date	e: Klik el	ller tryk for at	angive en dato.	
You	r name:	Bo Hasseriis Ha	nsen	
Mar	nuscript tit	le: Mod st	ørre gennemsigtighed: Uges	krift for Læger styrker fokus på interessekonflikter
Mar	nuscript nu	mber (if known): V205200	
are re third comn list a	elated to th parties wh nitment to relationshi	te content of your content of	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. ps/activities/interests as they relate to the current
perta antih In ite	nins to the expertensive m #1 below	epidemiology of e medication, ev v, report all sup	hypertension, you should ven if that medication is n	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months. Specifications/Comments
			whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
Time	e frame: Sin	ce the initial plan	nning of the work	
1	manuscript provision o materials, i	medical writing, cessing charges,	⊠ None	
				Click TAB in last row to add extra rows
Time	e frame: pas	t 36 months		
2		ontracts from (if not indicated above).	⊠ None	
3	Royalties o	r licenses	⊠ None	

4	Consulting fees	⊠ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	⊠ None	
	educational events		
6	Payment for expert	⊠ None	
	testimony		
7	Support for attending	⊠ None	
	meetings and/or travel		
8	Patents planned, issued or	M Name	
0	pending	⊠ None	
	pending		
9	Participation on a Data	⊠ None	
	Safety Monitoring Board		
	or Advisory Board		
10	Leadership or fiduciary	⊠ None	
	role in other board,		
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	⊠ None	
12	Possint of aguinment	M Name	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
13	Other financial or non- financial interests	⊠ None	

Please place an "X" next to the following statement to indicate your agreement:

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.